Decentering and Relapse/Recurrence in MBCT for Depression in Adults

Depression Clinical Trial

Official title:

The Association Between Decentering and Reductions in Relapse/Recurrence in Mindfulness-Based Cognitive Therapy for Depression in Adults: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05111665
• Other study ID #: H07-03046
• Status: Completed
• Phase: N/A
• Start date: February 14, 2008
• Est. completion date: October 31, 2008

Study information

• Verified date: October 2021
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions. The current study sought to examine the role of decentering, and other related variables, in the efficacy of Mindfulness-based cognitive therapy (MBCT) as compared to two active comparison conditions.

Method: Formerly depressed individuals (N = 227), randomly assigned to MBCT (n = 74), relaxation group therapy (RGT; n = 77) or treatment-as-usual (TAU; n = 76), completed self-report measures of decentering and symptoms of depression at pre-, mid-, and post-treatment, and relapse was assessed at 3, 6, 9, and 12 months, post-treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 227
• Est. completion date: October 31, 2008
• Est. primary completion date: October 31, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• a Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM IV-TR; American Psychiatric Association (APA), diagnosis of major depressive disorder (MDD) without psychotic features, in Full Remission;

• three or more prior major depressive episodes;

• age between 18 and 65 years;

• cognitive reactivity (CR) or mood-activated dysfunctional beliefs score greater than or equal to eight (see assessment procedure below);

• a score of less than 10 on the Hamilton Rating Scale for Depression (HRSD);

• minimum of a 10 week period free of psychotropic medication other than stable dosage of antidepressant medication for a minimum of four weeks;

• fluency in English; An increased cognitive reactivity score of eight points or more and,

• ability to give informed consent and complete questionnaires unassisted.

Exclusion Criteria:

• a diagnosis of bipolar disorder (past or present), schizophreniform disorders, substance abuse or dependence (current or within the past six months), borderline or antisocial personality disorder, or neurocognitive disorders;

• current psychotherapy or counselling more frequently than twice per month;

• current practice of meditation more than once per week or yoga more than twice per week;

• electroconvulsive therapy within the past six months; or

• self-reported ingestion of alcohol or other psychoactive substances within the past 48 hrs.

Related Conditions & MeSH terms

• Depression
• Depression in Remission
• Depressive Disorder
• Depressive Disorder, Major
• Recurrence

Intervention

Behavioral:
• Mindfulness-based Cognitive Therapy (MBCT)

• Relaxation Group Therapy (RGT)

• Treatment as usual (TAU)

Locations

Country	Name	City	State
Canada	Mark Lau	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major depressive disorder (MDD) relapse/recurrence - incidence of	Number of participants meeting criteria for relapse/recurrence of MDD during follow-up	12- month post-treatment follow-up
Primary	Change in major depressive disorder (MDD) relapse/recurrence - time to relapse/recurrence	Change in relapse/recurrence of MDD (i.e., survival) across follow-up	3-, 6-, 9-, and 12- month post-treatment follow-up
Secondary	Change in Beck Depression Inventory - Second Edition total scores	Change in symptoms of depression across MBCT treatment	Pre-, mid- (i.e., at week 4 of MBCT), and post-treatment (i.e., after 8 weeks of MBCT)